indication

Dementia

Competitive landscape projected to LB-102’s launch window

as of 2026-07-01
Competitive set
16
10 approved · 6 pipeline
Next guided milestone
2027-02-01
LB-102 — Adjunctive MDD (Ph2) trial initiation
LB-102 protection (issued)
2037
+4 pending families to 2047

Projection timeline

actual past → guided future · protection walls overlaid
96 events
2020
2024
2028
2032
2036
2040
2044
2048
today
LB-102 launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff

Competitive set

resolved drugs with trials in this indication
drugCompleted
Risperidone
US-approved 1993 · RISPERDAL
Phase 47 trials
OwnerJanssen, L.P. - Investigator Initiated Studies Program
Protection2042
drugCompleted
Quetiapine
US-approved 1997 · SEROQUEL XR
Phase 44 trials
OwnerAstraZeneca
Protection—
drugCompleted
Olanzapine
US-approved 1996 · ZYPREXA Intramuscular
Phase 44 trials
OwnerEli Lilly and Company
Protection2041
drugCompleted
Aripiprazole
US-approved 2002 · ABILIFY
Phase 42 trials
OwnerOtsuka Pharmaceutical Development & Commercialization, Inc.
Protection2041
drugCompleted
Pimavanserin
US-approved 2016 · NUPLAZID
Phase 31 trial
OwnerACADIA Pharmaceuticals Inc.
Protection2039
drugTerminated
Haloperidol
US-approved 1986 · Haldol Decanoate
Phase 31 trial
OwnerJanssen, L.P. - Investigator Initiated Studies Program
Protection—
drugTerminated
Ziprasidone
US-approved 2001 · Geodon
Phase 31 trial
OwnerPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Protection—
drugTerminated
Clozapine
US-approved 1989 · Clozaril
Phase 31 trial
OwnerShanghai Mental Health Center
Protection2028
drugTerminated
Paliperidone
US-approved 2006 · Erzofri extended-release
Phase 31 trial
OwnerJohnson & Johnson
Protection2041
drugRecruiting
Xanomeline-trospium (Cobenfy)
US-approved 2024 · Cobenfy
Phase 31 trial
OwnerKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Protection2039
drugTerminated
Fluphenazine
Pipeline · Phase 3
Phase 31 trial
OwnerHannover Medical School
Protection—
drugTerminated
Perphenazine
Pipeline · Phase 3
Phase 31 trial
OwnerJanssen, L.P. - Investigator Initiated Studies Program
Protection—
drugTerminated
Flupentixol
Pipeline · Phase 3
Phase 31 trial
OwnerTechnical University of Munich
Protection—
drugTerminated
Zuclopenthixol
Pipeline · Phase 3
Phase 31 trial
OwnerBirte Glenthoj
Protection—
drugTerminated
Sulpiride
Pipeline · Phase 3
Phase 31 trial
OwnerHannover Medical School
Protection—
drugTerminated
Amisulpride
Pipeline · Phase 3
Phase 31 trial
OwnerSanofi
Protection2038

Market size

prevalence as a range, not a number